Background: Fatigue is a prevalent issue among cancer patients. Cognitive behavioral therapy (CBT) is an individualized intervention that empowers patients and caregivers to actively participate in the treatment process. A recent systematic review and meta-analysis examined the impact of CBT on fatigue in cancer patients.
Methods: Articles published up to April 2023 were systematically searched in Scopus, PubMed, and the Web of Science using relevant keywords. All randomized clinical trials (RCTs) investigating the effects of CBT on fatigue in cancer patients were included. Statistical analyses were conducted using Stata version 14, with a significance level set at a -value of <0.05.
Results: The current systematic review and meta-analysis encompasses 10 RCTs. CBT demonstrated a significant reduction in fatigue scores among cancer patients [standardized mean difference (WMD): -2.50; 95%CI: -3.43, -1.56; I2 = 95.8%, < 0.001]. This effect was consistent across all subgroup analyses.
Conclusion: This study underscores the significant impact of CBT on fatigue in cancer patients. Further randomized clinical trials focusing on various cancer types are warranted to validate and build upon these findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757875 | PMC |
| http://dx.doi.org/10.3389/fpsyg.2024.1435110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The advent of immune checkpoint inhibitors (ICIs) has transformed the management of advanced and high-risk renal cell carcinoma (RCC). In the adjuvant setting, ICIs, such as pembrolizumab, aim to reduce the risk of recurrence following potentially curative nephrectomy. However, this therapeutic approach introduces unique challenges, particularly related to immune-related adverse events (irAEs).
View Article and Find Full Text PDFReal world experience on patterns of usage and toxicity profile of immunotherapy drugs in Indian patients: A prospective observational study.
Med J Armed Forces India
September 2023
Senior Adviser (Medicine) & Medical Oncologist, INHS Asvini, Mumbai, India.
Background: Immune checkpoint inhibitors (ICIs) are now considered revolutionary agents in the treatment of various cancers. Prospective data are limited on the patterns of usage and toxicity profile of these drugs. We planned this study for addressing the same in Indian patients.
View Article and Find Full Text PDFEffects of acteoside from on the plasma metabolome of cancer-related fatigue mice inoculated with colon cancer cells.
Front Pharmacol
January 2025
Department of Pharmacognosy, School of Pharmacy, Xinjiang Medical University, Urumqi, China.
Objective: To elucidate the metabolic mechanisms by which acteoside (ACT) isolated from alleviates cancer-related fatigue (CRF) in a murine model of colon cancer with cachexia.
Methods: BALB/c mice inoculated with C26 colon cancer cells were treated with paclitaxel (PTX, 10 mg/kg) and ACT (100 mg/kg) alone or in combination for 21 days. Fatigue-associated behaviors, tumor inhibition rate, and skeletal muscle morphology assessed by hematoxylin-eosin (H&E) staining and electron microscopy were evaluated.
Fitness, Body Composition, and Health Behaviors in Long-Term Survivors of Adolescent and Young Adult Cancers.
J Adolesc Young Adult Oncol
January 2025
Deakin University, Institute for Physical Activity and Nutrition (IPAN), Geelong, Australia.
To investigate cardiorespiratory fitness (CRF), body composition, health behaviors, and health-related quality of life (HRQoL) in adolescent and young adult cancer survivors (AYA-CS) compared with age-matched counterparts without a cancer diagnosis. This cross-sectional study recruited participants aged 15-25 years at the time of their cancer diagnosis and ≥ 5 years post-treatment. Participants completed cardiopulmonary exercise testing, dual-energy X-ray absorptiometry, food diaries, physical activity (PA), fatigue, and HRQoL questionnaires.
View Article and Find Full Text PDFComparison of Acute and Late toxicities with Daily vs. Every-Other-Day Five Fraction Partial Breast Radiation Therapy.
Pract Radiat Oncol
January 2025
Department of Radiation Oncology, Allegheny Health Network, Pittsburgh, PA. Electronic address:
Purpose/objective: Partial breast irradiation (PBI) delivered with intensity modulated radiation therapy (IMRT) over five fractions every other day (QOD) represents an attractive, convenient method of delivering adjuvant radiation therapy for well selected patients without compromising oncologic or toxicity outcomes. Condensing this regimen to a week of treatment through consecutive daily delivery may further increase patient convenience, though comparison of toxicities between daily and QOD regimens are limited.
Materials/methods: We retrospectively reviewed 507 patients from an institutional registry undergoing PBI for DCIS or early-stage breast cancer (T1-2N0/x) from 2015 to 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!